🔗 Share this article

A daily weight loss tablet may assist individuals reduce their body weight by up to 20%, as per a trial that could open doors for millions additional people to lose weight.

The Way the Drug Functions

This medication, called the oral treatment, targets the same gut hormone pathways as slimming injections such as Mounjaro and Wegovy. In a trial of 3,127 adults, one in five users who used the once-a-day pill for 72 weeks shed 20% or more of their total weight.

Slimming injections have been revolutionary, but pill versions are seen as a holy grail since they simpler to keep, share and administer, and may also be expected to be cheaper, offering fresh hope for millions attempting to lose weight.

Orforglipron is a GLP-1 agonist, a type of drug that helps lowering blood sugar readings, delays the digestion of meals and may reduce appetite.

Trial Results and Convenience

Slimming results seen among people taking the tablet is not as stark as those among patients using tirzepatide, but specialists believe the oral form is more accessible and convenient than shots.

Orforglipron has not been authorized by the FDA or regulators in other countries. The manufacturer has said it expects substantial demand once the oral treatment is launched.

During the trial, the over three thousand participants were split into groups receiving the medication tablets of different strengths, while others took a placebo, for the trial period.

Each of the patients were diagnosed with excess weight, indicating they had a body mass index score of 30 or over, but they were free from high blood sugar. Participants from multiple nations were involved in the research.

Significant Outcomes

Scientists discovered that after the study period people taking the lowest dose lost an mean of 7.5% of their weight. Those taking the highest dose shed an average of over 11% of their body weight.

In patients using the highest doses, 54.6% had a reduction of 10% or more of body weight, 36% had a loss of 15% or more, and almost one-fifth had a reduction of 20% or higher.

The team said additional wellness indicators also improved among people taking the medication, including better BP, a smaller waist size and a decrease in bad cholesterol.

The most common adverse reactions were gastrointestinal, which were described as manageable.

“In adults diagnosed with obesity, 72-week treatment with the medication resulted in notable decreases in weight than inactive treatment,” researchers noted.

Potential Impact

Health experts have hailed slimming treatments as game-changing. But injections come with additional logistical efforts for medical systems, so tablet forms might benefit millions more people trying to slim down.

Separate research indicates weight loss jabs may be effective on children starting from six who have obesity or have diabetes. However, digestive issues were “significantly more common” among children using the medications.

They said that extended observation durations in upcoming trials and more real-world research were “essential to establish the lasting effects.”